WCLC 2017: Ramucirumab Plus Docetaxel in Second-Line Treatment of Advanced NSCLC
Martin Reck, MD, PhD, of the Hospital Grosshandsdorf, Germany, presented a post-hoc analysis of the REVEL trial at the 2017 International Association for the Study of Lung Cancer (IASLC) World Conference on Lung Cancer (Abstract MA 03.06) in Yokohama, Japan. A subgroup of patients with advanced non–small cell lung cancer (NSCLC) who had aggressive tumor progression on first-line treatment seemed to benefit from ramucirumab and docetaxel therapy in the second-line setting, which is consistent with the results of the intent-to-treat population.
A total of 1253 patients in the REVEL trial who had advanced NSCLC of squamous or nonsquamous histology and demonstrated disease progression after chemotherapy were randomized to receive either ramucirumab and docetaxel or a placebo and docetaxel. Within the patient pool, 11% demonstrated tumor progression in up to 9 weeks (TTP ≤ 9 wk); 17%, in up to 12 weeks (TTP ≤ 12 wk); and 28%, in up to 18 weeks (TTP ≤ 18 wk) on first-line therapy.
Patients in all three subgroups demonstrated greater overall survival after treatment with the addition of ramucirumab compared with placebo. In the TTP ≤ 9 wk group, the 12-month survival rate was 47% with ramucirumab compared with 32% without. In the TTP ≤ 12 wk group, the 12-month survival rate was 34% with ramucirumab versus 23% without. In the TTP ≤ 18 wk group, the 120-month survival rate was 30% compared with 24% without.